비허온습방(脾虛蘊濕方)이 NC/Nga 아토피피부염 생쥐 모델의 피부 및 면역학적 변화에 미치는 영향

Suppression of DNCB-induced Dermatitis in NC/Nga Murine Model by Biheoonsupbang

  • 김정환 (대전대학교 한의과대학 병리학교실) ;
  • 최정준 (대전대학교 한의과대학 병리학교실) ;
  • 구영선 (대전대학교 한의과대학 내과학교실) ;
  • 노성수 (대전대학교 한의과대학 본초학교실) ;
  • 김동희 (대전대학교 한의과대학 병리학교실)
  • Kim, Jung-Hwan (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Choi, Jeong-June (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Koo, Young-Sun (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • Roh, Seong-Soo (Laboratory of Herbology, College of Oriental Medicine, Daejeon University) ;
  • Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • 발행 : 2007.06.25

초록

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by inflammatory cell infiltration in the skin. This study was performed to assess the therapeutic effects of BHOSB on the DNCB-induced dermatitis in NC/Nga mice, characterized by the onset of AD along with an increase the number of inflammatory cells and dysregulation of inflammatory mediators including cytokines and chemokines. BHOSB administration significantly reduced clinical dermatitis severity including pruritus, edema, eczematous and erythema. Histological findings indicated that the thickening of epidermis/dermis and dermal infiltration of inflammatory cells including mast cells were dramatically reduced. The suppression of dermatitis by BHOSB was accompanied by a decrease in the number of CD11b$^+$/Gr-1$^+$ immune cells in skin but not CD3$^+$/CCR3$^+$ cells. However, the number of CD3$^+$ cells was increased in BHOSB administrated NC/Nga mice. Oral administration of BHOSB significantly reduced the level of IL-6, TNF-a and eotaxin 2 mRNA in skin. These data suggest that BHOSB may be effective therapeutic agents for the treatment of AD.

키워드

참고문헌

  1. Sampson, H.A. Atopic dermatitis. Ann Allergy 69(6): 469-479, 1992
  2. Daniels, J. and Harper, J. The epidemiology of atopic dermatitis. Hosp Med 63(11):649-652, 2002 https://doi.org/10.12968/hosp.2002.63.11.1908
  3. Holden, C.A. and WE, P. Atopic dermatitis Blcackwell Science, Oxford, 1998
  4. Meagher, L.J., Wines, N.Y. and Cooper, A.J. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 43(4):247-254, 2002 https://doi.org/10.1046/j.1440-0960.2002.00610.x
  5. Leung, D.Y. and Soter, N.A. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44(1 Suppl):S1-S12, 2001 https://doi.org/10.1067/mjd.2001.109302
  6. Pastore, S., Mascia, F., Giustizieri, M.L., Giannetti, A. and Girolomoni, G. Pathogenetic mechanisms of atopic dermatitis. Arch Immunol Ther Exp (Warsz) 48(6):497-504, 2000
  7. Mihm, M.C. Jr., Soter, N.A., Dvorak, H.F. and Austen, K.F. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 67(3):305-312, 1976 https://doi.org/10.1111/1523-1747.ep12514346
  8. Schmid-Grendelmeier, P., Altznauer, F., Fischer, B., Bizer, C., Straumann, A., Menz, G., Blaser, K., Wuthrich, B. and Simon, H.U. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 169(2):1021-1027, 2002 https://doi.org/10.4049/jimmunol.169.2.1021
  9. Bandeira-Melo, C., Bozza, P.T. and Weller, P.F. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 109(3):393-400, 2002 https://doi.org/10.1067/mai.2002.121529
  10. Williams, H.C. Clinical practice. Atopic dermatitis. N Engl J Med 352(22):2314-2324, 2005 https://doi.org/10.1056/NEJMcp042803
  11. Kitaura, J., Kinoshita, T., Matsumoto, M., Chung, S., Kawakami, Y., Leitges, M., Wu, D., Lowell, C.A. and Kawakami, T. IgE- and IgE+ Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 105(8):3222-3229, 2005 https://doi.org/10.1182/blood-2004-11-4205
  12. Plotz, S.G., Simon, H.U., Darsow, U., Simon, D., Vassina, E., Yousefi, S., Hein, R., Smith, T., Behrendt, H. and Ring, J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349(24):2334-2339, 2003 https://doi.org/10.1056/NEJMoa031261
  13. Leung, D.Y. and Bieber, T. Atopic dermatitis. Lancet 361(9352):151-160, 2003 https://doi.org/10.1016/S0140-6736(03)12193-9
  14. Cooper, K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 102(1):128-137, 1994 https://doi.org/10.1111/1523-1747.ep12371746
  15. 한방병리학교재편찬위원회. 한방병리학, 한의문화사, pp 52-57, 2007
  16. 대한동의생리학회. 동의생리학, 일중사, p 332, 337, 2005
  17. 張志禮. 張志禮皮膚病臨床經驗輯要, 中國醫藥科技出版社, p 15, 23, 43, 2002
  18. 王保方 外. 皮膚病中醫診斷學, 人民衛生出版社, p 23, 24, 2000
  19. 朴俊華. 皮膚性病科節技, 科學技術文獻出版社, p 2, 33, 42, 80, 2002
  20. Vestergaard, C., Yoneyama, H. and Matsushima, K. The NC/Nga mouse: a model for atopic dermatitis. Mol Med Today 6(5):209-210, 2000 https://doi.org/10.1016/S1357-4310(00)01683-X
  21. Heishi, M., Imai, Y., Katayama, H., Hashida, R., Ito, M., Shinagawa, A. and Sugita, Y. Gene expression analysis of atopic dermatitis-like skin lesions induced in NC/Nga mice by mite antigen stimulation under specific pathogen-free conditions. Int Arch Allergy Immunol 132(4):355-363, 2003 https://doi.org/10.1159/000074903
  22. Robert, C. and Kupper, T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341(24):1817-1828, 1999 https://doi.org/10.1056/NEJM199912093412407
  23. Clevers, H., Alarcon, B., Wileman, T. and Terhorst, C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6: 629-662, 1988 https://doi.org/10.1146/annurev.iy.06.040188.003213
  24. Silny, W. Atopic dermatitis. IV. Granulocyte chemotaxis. Przegl Dermatol 70(5-6):475-480, 1983
  25. Hu, Z.Q., Kobayashi, K., Zenda, N. and Shimamura, T. Tumor necrosis factor-alpha- and interleukin-6-triggered mast cell development from mouse spleen cells. Blood 89(2):526-533, 1997
  26. Yawalkar, N., Uguccioni, M., Scharer, J., Braunwalder, J., Karlen, S., Dewald, B., Braathen, L.R. and Baggiolini, M. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 113(1):43-48, 1999 https://doi.org/10.1046/j.1523-1747.1999.00619.x